OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab)

The FDA on April 16, 2018 granted approvals to OPDIVO® and YERVOY® in combination, for the treatment of intermediate or poor risk, previously untreated advanced Renal Cell Carcinoma. OPDIVO® and YERVOY® are products of Bristol-Myers Squibb Co.